Stay updated on AK104 Bispecific Antibody Clinical Trial
Sign up to get notified when there's something new on the AK104 Bispecific Antibody Clinical Trial page.

Latest updates to the AK104 Bispecific Antibody Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedA new site revision (v3.4.2) was added, and an existing notice about government funding was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference1.0%

- Check26 days agoChange DetectedA government funding notice banner was added and the page revision updated to v3.4.1 (replacing v3.4.0) in the page header and history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference1%

- Check33 days agoChange DetectedNew UI elements include a glossary toggle and color-coded change highlights (green for additions and red for deletions) to show how the study record differs across versions. The revision tag has been updated from v3.3.4 to v3.4.0 and the No FEAR Act data label has been updated to 'No FEAR Act Data'.SummaryDifference1%

- Check47 days agoChange DetectedThe Record History shows the addition of revision v3.3.4 and the removal of revision v3.3.3, updating the record's version history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check68 days agoChange DetectedAdded a new revision entry 'Revision: v3.3.3' and removed 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' from the footer.SummaryDifference0.2%

- Check90 days agoChange DetectedThe Record History shows a new revision v3.3.2 added and v3.3.1 removed, which is a minor administrative update and does not affect study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to AK104 Bispecific Antibody Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AK104 Bispecific Antibody Clinical Trial page.